Steven J Frucht1. 1. Columbia-Presbyterian Medical Center, New York, NY 10032, USA. sf216@columbia.edu
Abstract
BACKGROUND: Over the past decade, the treatment of Parkinson disease (PD) has undergone tremendous changes. New drugs have been introduced to manage the cardinal motor symptoms of PD, and other agents have been borrowed to treat the nonmotor manifestations of the illness. For neurologists faced with the task of treating PD patients, the available array of medications may be confusing and intimidating. REVIEW SUMMARY: In this review, I summarize the newest approved medications for the treatment of PD, including the new dopamine agonists and catechol-O-methyl-transferase inhibitors. I also describe agents that are used to treat common problems in PD patients, including hallucinations, orthostasis, nausea, erectile dysfunction, depression, and memory loss. Guidelines for handling common scenarios in PD patients will be illustrated by 10 case histories. Finally, the most promising PD drugs that are currently in development will be reviewed. CONCLUSIONS: Neurologists have a vast armamentarium to treat both motor and nonmotor manifestations of PD. Understanding this array allows the astute clinician to improve the lives of their patients with PD.
BACKGROUND: Over the past decade, the treatment of Parkinson disease (PD) has undergone tremendous changes. New drugs have been introduced to manage the cardinal motor symptoms of PD, and other agents have been borrowed to treat the nonmotor manifestations of the illness. For neurologists faced with the task of treating PDpatients, the available array of medications may be confusing and intimidating. REVIEW SUMMARY: In this review, I summarize the newest approved medications for the treatment of PD, including the new dopamine agonists and catechol-O-methyl-transferase inhibitors. I also describe agents that are used to treat common problems in PDpatients, including hallucinations, orthostasis, nausea, erectile dysfunction, depression, and memory loss. Guidelines for handling common scenarios in PDpatients will be illustrated by 10 case histories. Finally, the most promising PD drugs that are currently in development will be reviewed. CONCLUSIONS: Neurologists have a vast armamentarium to treat both motor and nonmotor manifestations of PD. Understanding this array allows the astute clinician to improve the lives of their patients with PD.
Authors: Wayne A Hening; Richard P Allen; William G Ondo; Arthur S Walters; John W Winkelman; Philip Becker; Richard Bogan; June M Fry; David B Kudrow; Kurt W Lesh; Andreas Fichtner; Erwin Schollmayer Journal: Mov Disord Date: 2010-08-15 Impact factor: 10.338
Authors: Irena Rektorova; Marek Balaz; Jindra Svatova; Katerina Zarubova; Igor Honig; Vaclav Dostal; Silvie Sedlackova; Igor Nestrasil; Jiri Mastik; Martin Bares; Jana Veliskova; Ladislav Dusek Journal: Clin Neuropharmacol Date: 2008 Sep-Oct Impact factor: 1.592
Authors: Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria Journal: Lancet Neurol Date: 2013-04-03 Impact factor: 44.182
Authors: Ernesto Miranda-Morales; Karin Meier; Ada Sandoval-Carrillo; José Salas-Pacheco; Paola Vázquez-Cárdenas; Oscar Arias-Carrión Journal: Front Mol Neurosci Date: 2017-07-18 Impact factor: 5.639